UroGen Pharma Ltd. Operating Lease, Expense
UroGen Pharma Ltd. (URGN) reported Operating Lease, Expense of $1.20 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2020-03-02
- UroGen Pharma Ltd. operating lease, expense for fiscal 2019 was $1.20M, a 0.00% change from fiscal 2018.
- UroGen Pharma Ltd. operating lease, expense for fiscal 2018 was $1.20M, a 100.00% increase from fiscal 2017.
- UroGen Pharma Ltd. operating lease, expense for fiscal 2017 was $600.00K.
| Period end | Operating Lease, Expense 12 month |
|---|---|
| 2019-12-31 | $1.20M 10-K · filed 2020-03-02 |
| 2018-12-31 | $1.20M 10-K · filed 2020-03-02 |
| 2017-12-31 | $600.00K 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |